Cardio Diagnostics Inc. (CDIOW)
NasdaqCM: CDIOW
· Real-Time Price · USD
0.01
-0.01 (-50.00%)
At close: Aug 14, 2026, 9:44 AM
Cardio Diagnostics Inc. (CDIOW) Stock Price, Analysis & Data
-50.00% (1D)
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | 14.45K |
| Net Income (ttm) | -6.47M |
| Beta | 2.22 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | n/a |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 16,223 |
| Avg. Volume (20D) | |
| Open | 0.02 |
| Previous Close | 0.02 |
| Day's Range | 0.01 - 0.01 |
| 52-Week Range | 0.01 - 0.01 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CDIOW
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platfo...
IPO Date Jul 17, 2026
Employees 15
Stock Exchange NasdaqCM
Ticker Symbol CDIOW
Website https://cdio.ai
Financial Performance
In 2025, Cardio Diagnostics's revenue was 14.82K, a decrease of -57.51% compared to the previous year's 34.89K. Earnings were -6.5M, a decrease of -22.49%.
Financial Statements